UEGweek 2025

AI AI captain! - AI improves histological diagnostics

A new oral α4β7 integrin inhibitor - more questions…

New rumours about small molecules

IL-23 inhibition: sc is nice, oral is better ?!

Are JAK inhibitors better than their reputation?

If it helps, can we stop it? Drug withdrawel in IBD

Fistulizing perianal disease - still challenging!

Complete disease clearence - the quest for the optimal…

Timing is everything - surgical intervention in CD

Modifying the diet does have an impact on IBD risk!

JAKis may be safer than you probably think they are!

Efficacy of sc induction with guselkumab therapy in UC

T2T in UC - first piece of restrospective evidence

Finally time to stop the automatic continuation of…

Endlich Zeit das automatisierte 5-ASA Weiterführen zu…

T2T nella CU – prime evidenze retrospettive

Effektivität der s.c. Induktion mit Guselkumab bei UC

To stop or not to stop? That is the question (in…

Is it possible to stop anti-TNF treatment in early CD…

Therapy sequence: guselkumab is possible after…

Efficacy of guselkumab in patients with inadequate…

Early treatment with adalimumab does not allow for…

Patients with early Crohn’s disease on adalimumab: can…

10 years after the LIR!C trial – the update of the…

Can we stop Adalimumab in CD patients achieving…

Perianal CD - it's associated with low infliximab…

Injecting in fistulas: the never ending story?

Possiamo sospendere Adalimumab in pazienti affetti da…

10 lat po badaniu LIR!C – aktualizacja danych o…

Therapiesequenz: Guselkumab nach Ustekinumab-Versagen…

Peut-on arrêter un anti-TNF dans la maladie de Crohn…

Efficacia di Gusekumab in pazienti affetti da malattia…

הזרקת תאים לפיסטולה במחלת קרוהן- הסיפור שאינו נגמר?

Czy przerywać skuteczne leczenie u pacjentów z chorobą…

Go for oral anti-α4β7!

CAR-T cells in refractory UC – a new option for the…

Oral mufemilast, a PDE4 inhibitor, for moderate to…

B-cell depletion in refractory ulcerative colitis –…

Obefazimod - a new mechanism of action for the…

Icotrokina - a new oral drug for blocking IL-23

Puntare sugli anti-α4β7 orali!

Les cellules CAR-T dans la RCH réfractaire – une…

Obefazimod - Une nouvelle classe thérapeutique pour la…

B-Zell-Depletion bei refraktärer Colitis Ulcerosa -…

Mufemilast, αναστολέας της PDE4, για θεραπεία από του…

Obefazimod induction therapy is effective and well…

Long term persistence of ustekinumab in Real-Life…

Histo-endoscopic endpoint in long-term extension of…

Etrasimod in mild to moderate UC

Real-world short-term efficacy and safety of…

Obefazimod in moderate to severe UC

Etrasimod nella colite ulcerosa da lieve a moderata

Endlich Zeit das automatisierte 5-ASA Weiterführen zu…

Efectividad y seguridad en vida real a corto plazo de…

Eficacia y seguridad a corto plazo (8 semanas) de…

Μακροχρόνια αποτελεσματικότητα της ουστεκινουμάμπης σε…

JAK-Inhibitoren sind vielleicht sicherer als Sie…

Obefazimod-Induktionstherapie ist effektiv und gut…

Guselkumab sc in crohn’s disease with inadequate…

Ustekinumab in perianal Crohn’s disease

Guselkumab sc en enfermedad de crohn con respuesta…

Dane typu real-life a badania kliniczne risankizumabu w…

Sigmoid volvulus: an old problem, still waiting for…

IUS as a patient- and environmental-friendly tool in…

Steroid-sparing effect of upfront Vedolizumab in…

AI-endoscopy ready - is it a game changer?

When nanoparticles calm down celiac-specific T-cells

Real-life vs clinical trials IBD patients access to…

Let's go green! ecological effect of patient monitoring

Vedolizumab - another option for JAKi-induced…

Reassuring safety signals of JAKis in pregnant IBD…

Selection criteria for randomized clinical trials in…

Looking for the black sheep pathways

New insights from the GEM trail

IBD outcome in a large national cohort from spain

Eosinophilic esophagitis doesn’t seem to increase the…

JAK-Inhibitoren und Schwangerschaft bei CED

Wenn Nanopartikel zöliakiespezifische T-Zellen…

פתלת הפרשדון....בעיה מוכרת שעדין מחכה לפתרון

Eosinophile Ösophagitis ist kein Risikofaktor für ein…

Segnali si sicurezza rassicuranti in donne affette da…

Auf der Suche nach den schwarzen Pathway-Schafen

Co ma wspólnego USG jelit w IBD z ekologią?

Vedolizumab - eine zusätzliche Therapieoption bei…

Verso il verde! L’impatto ecologico del monitoraggio…

Critères de sélection des essais cliniques randomisés…

Risparmio di steroidi in pazienti con colite indotta da…